The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway

Chand Khanna and colleagues describe the work of the Comparative Oncology Trials Consortium (COTC), which provides infrastructure and resources to integrate naturally occurring dog cancer models into the development of new human cancer drugs, devices, and imaging techniques.

Saved in:
Bibliographic Details
Published in:PLoS medicine 2009-10, Vol.6 (10), p.e1000161-e1000161
Main Authors: Gordon, Ira, Paoloni, Melissa, Mazcko, Christina, Khanna, Chand
Format: Article
Language:English
Subjects:
Alliances
Animals
Animals, Domestic
Antineoplastic Agents - therapeutic use
Biology
Cancer therapies
Clinical trials
Clinical Trials as Topic - veterinary
Clinical Trials, Phase I as Topic
Design
Dog Diseases - drug therapy
Dogs
Drug Screening Assays, Antitumor
Health in Action
Histology
Humans
Immune system
Infrastructure
Integrated approach
Models, Animal
Multicenter Studies as Topic - veterinary
National Cancer Institute (U.S.) - organization & administration
Neoplasms - drug therapy
Neoplasms - veterinary
Oncology
Oncology/Oncology Agents
Pharmaceutical industry
Species Specificity
Studies
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chand Khanna and colleagues describe the work of the Comparative Oncology Trials Consortium (COTC), which provides infrastructure and resources to integrate naturally occurring dog cancer models into the development of new human cancer drugs, devices, and imaging techniques.
ISSN:1549-1676
1549-1277
1549-1676
DOI:10.1371/journal.pmed.1000161